Biovail Cardizem LA Bedtime/Morning Dosing Flexibility Included In Label
Executive Summary
Biovail will launch Cardizem LA on April 2 following FDA's Feb. 6 approval of the "graded-release," once-daily diltiazem for hypertension
You may also be interested in...
Biovail facing grand jury investigation
The Massachusetts Attorney General's office is pursuing a grand jury investigation of Biovail's 2003 launch of Cardizem LA (diltiazem), particularly its program to encourage doctors to prescribe the long-acting formulation of the antihypertensive drug. Under this program, physicians who prescribed the drug to up to 15 patients and completed a questionnaire were entitled to receive $1,000. In launching Cardizem, Biovail said it would be aggressive in seeking to convert users of other diltiazem products, including its own Cardizem CD, to Cardizem LA (1"The Pink Sheet" Feb. 10, 2003, p. 27). The AG's office began an administrative inquiry into the program in 2003, and at that time the HHS Office of Inspector General launched a similar investigation...
Biovail facing grand jury investigation
The Massachusetts Attorney General's office is pursuing a grand jury investigation of Biovail's 2003 launch of Cardizem LA (diltiazem), particularly its program to encourage doctors to prescribe the long-acting formulation of the antihypertensive drug. Under this program, physicians who prescribed the drug to up to 15 patients and completed a questionnaire were entitled to receive $1,000. In launching Cardizem, Biovail said it would be aggressive in seeking to convert users of other diltiazem products, including its own Cardizem CD, to Cardizem LA (1"The Pink Sheet" Feb. 10, 2003, p. 27). The AG's office began an administrative inquiry into the program in 2003, and at that time the HHS Office of Inspector General launched a similar investigation...
Biovail sales force expansion
Biovail will create two new specialty sales forces in 2004 - one for cardiovascular products and one for dermatology and obstetrics. The expansion follows the termination of a co-promotion agreement with Reliant, which had been promoting Biovail's Cardizem LA and other cardiovascular products with 250 reps (1"The Pink Sheet" Feb. 10, 2003, p. 27). Reliant will receive $62 mil. as "extinguishment of trailing royalty obligations," Biovail says. The dermatology/obstetrics force will promote the herpes treatment Zovirax...